VistaGen Therapeutics
VTGN

$3.13

4.33%

Market Cap: $84.7M

About: Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Employees: 41

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

246% more call options, than puts

Call options by funds: $2.09M | Put options by funds: $606K

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

2% more funds holding

Funds holding: 42 [Q1] → 43 (+1) [Q2]

2.01% more ownership

Funds ownership: 64.05% [Q1] → 66.06% (+2.01%) [Q2]

32% less capital invested

Capital invested by funds: $90.9M [Q1] → $61.6M (-$29.4M) [Q2]

43% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 14

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for VTGN.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy

VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2025 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince - COO Conference Call Participants Andrew Tsai - Jefferies Tim Lugo - William Blair Madison Elsaadi - B. Riley Securities Operator Ladies and gentlemen, greetings and welcome to Vistagen Therapeutics Fiscal Year 2025 First Quarter Corporate Update Conference Call.

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

Zacks Investment Research

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.94 per share a year ago.

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 first quarter ended June 30, 2024, and provided a corporate update. “Building on the success of our PALISADE-2 Phase 3 trial of fasedienol,.

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Tuesday, August 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 first quarter en.

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

3 Stocks Under $15 That Could Make You a Millionaire

Lately, the stock market has been soaring thanks mostly to growth stocks trading at sky-high valuations. While rate cuts could potentially boost markets, caution is still warranted for most investors.

3 Stocks Under $15 That Could Make You a Millionaire

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global intellectual property portfolio after receiving multiple new patents related to the use of PH80 for the treatment of migraine. PH80 is a non-systemic, hormone.

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2024 Earnings Conference Call June 11, 2024 5:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - Chief Executive Officer Cindy Anderson - Chief Financial Officer Josh Prince - Chief Operating Officer Conference Call Participants Tim Lugo - William Blair Operator Greetings, and welcome to the Vistagen Therapeutics Fiscal Year-End 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode.

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year ended March 31, 2024, and provided a corporate update. “Vistagen's fiscal 2024 proved to be a year full of remarkable accomplishments. Most notably, with.

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 ended March 31, 2024 and provide a corporate update. Event: Vistagen Fis.

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

See News Rankings